A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Lars Fruergaard Jørgensen might not be a household name, but his company’s drug is. And its success has thrust him — ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...